Non-Vitamin K oral anticoagulant treatment – behind the mask there is a story

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Jan 3, 2019
DOI: https://doi.org/10.22551/2018.21.0504.10143
Mădălina-Ștefana Mihai Anca Ouatu Anca Trifan Cătălin Sfarti

Abstract

Pelvic radiation disease is a term related to complications developed after radiotherapy used for pelvic cancers. Symptomatology can be overt, dull or even absent depending on variable factors. We present the case of a 78-year-old female patient with a declared post-partum hysterectomy, known cardiovascular disease, and fatigue and dizziness as main symptoms. She was diagnosed with pelvic radiation disease only after the symptoms were triggered by a non-vitamin K anticoagulant treatment and carefully reassessed anamnesis. Despite it being a predictable condition in patients receiving pelvic radiation, the disease is underdiagnosed, clinicians often overlooking the scale of the problem by treating the symptoms or by focusing on a small fraction of the disease within their medical branch. The case presented displays the value of shifted focus from survivorship to life quality and the importance of patient-tailored management. Sometimes, complementary therapy uncovers a masked illness which can initially be a real challenge but early diagnosis can lead to a satisfactory medical outcome.

##plugins.themes.bootstrap3.article.details##

Keywords

pelvic radiation disease, non-vitamin K oral anticoagulants, atrial fibrillation

References
1. Morris KA, Haboubi NY. Pelvic radiation therapy: Between delight and disaster. World J Gastrointest Surg 2015; 7(11):279-288.
2. Dörr W. Radiobiology of tissue reactions. Ann ICRP 2015; 44(1):58-68.
3. Do NL, Nagle D, Poylin VY. Radiation proctitis: current strategies in management. Gastroenterol Res Pract 2011; 2011:917941.
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38):2893-2962.
5. Deutsch D, Boustière C, Ferrari E, Albaladejo P, Morange PE, Benamouzig R. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol 2017; 10(6):495-505.
6. Vanneste BG, Van De Voorde L, de Ridder RJ, Van Limbergen EJ, Lambin P, van Lin EN. Chronic radiation proctitis: tricks to prevent and treat. Int J Colorectal Dis 2015; 30(10):1293-1303.
7. Denham JW, Hauer-Jensen M. Radiation induced bowel injury: a neglected problem. Lancet 2013; 382:2046-2047.
8. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2013; 19(1):82-93.
9. Desai JC, Chatterjee P, Friedman K, Aisenberg J. Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants. Am J Gastroenterol 2016; 3:13-21.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875–1876.
11. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long-term multicenter observational study of Dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study. Circulation 2013; 128:237–243.
12. Manesh RP, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
13. Farcas A, Bataga S, Cijevschi C, et al. Gastrointestinal endoscopy in patients on direct oral anticoagulants. a consensus paper of the Romanian Society of Gastroenterology and Hepatology. J Gastrointestin Liver Dis 2018; 27(2):179-187.
14. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of Dabigatran compared with Warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
15. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23(11):1954-1963.
16. Blech S, Ebner T, Ludwig-Schwellinger E, Stangierand J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, Dabigatran, in humans. Drug Metab Dispos 2008; 36(2):386-399.
17. Clemens A, Strack A, Noack H, et al. Anticoagulant-related gastrointestinal bleeding - could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med 2014; 46:672–678.
18. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11):981-992.
How to Cite
Mihai, M.- Ștefana, Ouatu, A., Trifan, A., & Sfarti, C. (2019). Non-Vitamin K oral anticoagulant treatment – behind the mask there is a story. Archive of Clinical Cases, 5(4), Arch Clin Cases 2018; 5(4):152-158. https://doi.org/10.22551/2018.21.0504.10143
Issue
Vol. 5 No. 4 (2018)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Mihai, M.- Ștefana, Ouatu, A., Trifan, A., & Sfarti, C. (2019). Non-Vitamin K oral anticoagulant treatment – behind the mask there is a story. Archive of Clinical Cases, 5(4), Arch Clin Cases 2018; 5(4):152-158. https://doi.org/10.22551/2018.21.0504.10143